Kado Mixture Cloud g after radiation treatment of Graves ophthalmopathy 131 short-term efficacy of.docVIP

 PAGE \* MERGEFORMAT 10 Kado Mixture Cloud g after radiation treatment of Graves ophthalmopathy 131 short-term efficacy of 【Abstract】 Objective To investigate the Kado mixture with the “MDP” the treatment of Graves ophthalmopathy after radiation 131 Ⅰ short-term clinical efficacy. Methods 131 Ⅰ after radiation therapy within 1 month of the 48 cases of patients with Graves ophthalmopathy were randomly divided into test group and control group, experimental group were Kado Mixture “Cloud g” treatment in the control group alone, “MDP” treatment, before and after treatment in April by the same ophthalmologist examination in patients with eye conditions in patients with simultaneous determination of thyroid hormone levels. Treatment for 4 months after the adoption of NOSPECS classification standards and indicators to determine efficacy of eye, using SPSS7.5 statistical software for analysis. The results for the 131 Ⅰ radionuclide therapy patients, a separate application “MDP” treatment to control symptoms slowly, while the experimental group of cases signs of Graves ophthalmopathy and thyroid hormone levels were higher and significantly improved. The length of the efficacy and treatment related to the performance of many better treatment for the elderly, invalid are from the course of less than 30 d. Conclusion Kado Mixture “cloud g” 131 Ⅰ treatment of Graves ophthalmopathy after radiation has a high efficacy, but also overcome the Graves ophthalmopathy 131 Ⅰ after radiation therapy side effects, if conditions are appropriate to extend the efficacy of treatment may be given a better has clinical value and development potential, worthy to be popularized. Keywords: Kado mixture cloud g 131 Ⅰ radiotherapy Graves ophthalmopathy Graves ophthalmopathy (Graves ophthalmopathy, GO) cause is not yet clear, and auto-immune related. The possible pathogenesis is that the blood of thyroid follicular cell antigen for the T-cells recognize a common epitope,